Mutant SpoT protein and method for producing L-amino acids using the same

Abstract

The present application relates to a mutant SpoT protein and a method for producing L-amino acids using the same.

Description

[Technical field]

[0001] The present application relates to a mutant SpoT protein and a method for producing L-amino acids using the same. [Background technology]

[0002] In the early days, the microorganisms used for L-amino acid production were mainly selected strains that exhibited analogue resistance due to chemical or physical mutations. However, with the rapid development of recombinant gene technology in the 1990s and the elucidation of regulatory mechanisms at the molecular level, recombinant strains produced using genetic engineering techniques are now mainly used.

[0003] The stringent response is a bacterial response to various stress situations. It was initially discovered as a phenomenon in which protein synthesis was suppressed under conditions of amino acid deficiency, but it is now known to be a response to various stress environments through changes in various physiological activities such as the cessation of cell division and the inhibition of DNA replication (Non-Patent Documents 1, 2). The core reaction of the stringent response is initiated by guanosine pentaphosphate (pppGpp) and guanosine tetraphosphate (ppGpp). Since these two molecules are functionally similar, they are generally referred to as (p)ppGpp.

[0004] In E. coli, pppGpp is produced by a pppGpp synthase called RelA. The RelA protein monitors the state of protein translation in the ribosome. When there is a shortage of protein in the cell, the concentration of tRNA that does not have an amino acid increases, but when this tRNA binds to the ribosome, RelA is activated. RelA produces pppGpp by reacting guanosine triphosphate (GTP) with adenosine triphosphate (ATP). When the amino acid concentration in the cell increases and the balance is restored, (p)ppGpp is hydrolyzed by the SpoT protein. The SpoT protein has not only the decomposition activity of (p)ppGpp but also the synthesis activity (Non-Patent Document 3). However, the relationship between the SpoT protein and amino acid production is still unknown.

Prior Art Documents

Patent Documents

[0005]

Patent Document 1

Patent Document 2

Patent Document 3

Non-Patent Documents

[0006]

Non-Patent Document 1

Non-Patent Document 2

Non-Patent Document 3

Non-Patent Document 4

Non-Patent Document 5

Non-Patent Document 6

Non-Patent Document 7

Non-Patent Document 8

[0007] The present application provides a mutant SpoT protein and a method for producing an L-amino acid using the same. [Means for solving the problem]

[0008] The present application aims to provide a mutant SpoT protein comprising a substitution of the amino acid corresponding to position 262 in the sequence of SEQ ID NO:1 with another amino acid.

[0009] Another object of the present application is to provide a polynucleotide encoding the mutant SpoT protein and a vector comprising the same.

[0010] An object of the present application is to provide a microorganism of the genus Escherichia comprising at least one of the mutant SpoT protein, a polynucleotide encoding the mutant SpoT protein, and a vector comprising the polynucleotide.

[0011] Another object of the present application is to provide a method for producing an L-amino acid, comprising the step of culturing the microorganism in a medium.

[0012] Furthermore, the present application aims to provide a method for improving an L-amino acid producing ability of a microorganism, which comprises the step of modifying the microorganism so that it expresses the mutant SpoT protein. Effect of the Invention

[0013] By using the mutant protein of the present application, L-amino acids can be produced effectively. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] These will be described in detail below. Each description and embodiment disclosed in this application is also applicable to other descriptions and embodiments. That is, all combinations of various elements disclosed in this application are included in this application. In addition, this application is not limited to the following specific description. Furthermore, many papers and patent documents are referenced throughout this specification, and citations thereof are provided. The disclosure contents of the cited papers and patent documents are incorporated in their entirety into this specification by reference, thereby more clearly explaining the state of the art to which the present invention belongs and the contents of the present invention.

[0015] One aspect of the present application provides a mutant SpoT protein comprising a substitution of the amino acid corresponding to position 262 in the sequence of SEQ ID NO:1 with another amino acid.

[0016] The mutant SpoT protein means a polypeptide having the activity of SpoT protein, or a mutant protein in SpoT protein that contains a substitution of the amino acid corresponding to the 262nd position from the N-terminus of the amino acid sequence of SEQ ID NO: 1 with another amino acid.

[0017] In one embodiment, the other amino acids may be selected from glycine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, and histidine.

[0018] In a mutant protein according to any of the previous embodiments, said other amino acids may be selected from polar amino acids.

[0019] In the mutant protein according to any of the previous embodiments, the other amino acids may be selected from serine, threonine, cysteine, tyrosine, asparagine and glutamine.

[0020] In the mutant protein according to any of the above-mentioned Examples, the mutant SpoT protein may have any of the amino acid sequences represented by SEQ ID NOs: 19 to 24, may contain the amino acid sequence, or may be essentially consisting of the amino acid sequence.

[0021] In a mutant protein according to any of the above-mentioned embodiments, the mutant SpoT protein may comprise a substitution of the amino acid corresponding to position 262 in the amino acid sequence of SEQ ID NO:1 with another amino acid, and may comprise an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more, but less than 100%, homology or identity to the amino acid sequence represented by SEQ ID NO:1.

[0022] Furthermore, it goes without saying that mutant proteins having an amino acid sequence in which part of the sequence has been deleted, modified, substituted, conservatively substituted or added are also included in the present application, so long as the amino acid sequence has such homology or identity and exhibits efficacy equivalent to that of the mutant protein of the present application.

[0023] For example, the mutant proteins may have sequence additions or deletions, naturally occurring mutations, silent mutations or conservative substitutions at the N-terminus, C-terminus and / or internally of the amino acid sequence that do not change the function of the mutant proteins of the present application.

[0024] The term "conservative substitution" refers to the replacement of an amino acid with another amino acid having similar structural and / or chemical properties. Such amino acid substitutions may generally be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic nature of the residues. Typically, conservative substitutions have little or no effect on the activity of a protein or polypeptide.

[0025] The mutant proteins of the present application are also referred to as "protein variants."

[0026] In the present application, the term "variant" refers to a polypeptide that differs from the amino acid sequence of the variant by conservative substitution and / or modification of at least one amino acid, but maintains its functions or properties. Such variants can generally be identified by modifying at least one amino acid in the amino acid sequence of the polypeptide and evaluating the properties of the modified polypeptide. That is, the ability of the variant is improved, unchanged, or decreased compared to the polypeptide before the mutation. Some variants also include variants in which at least one portion, such as an N-terminal leader sequence or a transmembrane domain, has been removed. Other variants also include variants in which a portion has been removed from the N- and / or C-terminus of a mature protein. The term "variant" may be a mutant type, a modification, a mutant polypeptide, a mutated protein, or a mutation (in English, modification, modified polypeptide, modified protein, mutant, mutein, divergent, etc.), but any term that means a mutation may be used. For the purposes of this application, said variant may be a polypeptide comprising an amino acid sequence in which the amino acid corresponding to position 262 of the amino acid sequence of SEQ ID NO:1 has been replaced with another amino acid.

[0027] The variant may also include deletions or additions of amino acids that have minimal effect on the properties and secondary structure of the polypeptide. For example, the N-terminus of the variant may be linked to a signal (or leader) sequence involved in co-translationally or post-translationally protein translocation. The variant may also be linked to other sequences or linkers to allow identification, purification, or synthesis.

[0028] In this application, "homology" or "identity" refers to the degree of similarity between two given amino acid or nucleotide sequences, expressed as a percentage. Homology and identity are often used interchangeably.

[0029] Sequence homology or identity of conserved polynucleotides or polypeptides may be determined by standard sequence algorithms, with default gap penalties established by the program used. Substantially homologous or identical sequences will generally hybridize to all or a portion of the sequence under moderate or high stringent conditions. Hybridization, of course, also includes hybridization to polynucleotides having common codons in the polynucleotide or codons that take into account codon degeneracy.

[0030] Whether any two polynucleotide or polypeptide sequences have homology, similarity or identity can be determined using known computer algorithms such as the "FASTA" program with default parameters as in, for example, Non-Patent Document 4. Alternatively, it can be determined using the Needleman-Wunsch algorithm (Non-Patent Document 6), as implemented in the Needleman program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Non-Patent Document 5) (version 5.0.0 or later), which includes the GCG program package (Non-Patent Document 7), BLASTP, BLASTN, FASTA (Non-Patent Documents 8, 9 and 10). For example, BLAST or Clustal W from the National Center for Biotechnology Information can be used to determine homology, similarity or identity.

[0031] Homology, similarity or identity of polynucleotides or polypeptides can be determined by comparing sequence information using a GAP computer program such as GAP (1999) (1999) (1999) (1999) (1999). Briefly, the GAP program defines the number of similar sequence symbols (i.e., nucleotides or amino acids) divided by the total number of symbols in the shorter of the two sequences. Default parameters for the GAP program include (1) a binary comparison matrix (identity takes a value of 1 and non-identity takes a value of 0) and a weighted comparison matrix (or EDNAFULL (the EMBOSS version of NCBI NUC4.4) substitution matrix) of GAP (1999) (1999) (2) a penalty of 3.0 for each gap and an additional penalty of 0.10 for each symbol in each gap (or a gap open penalty of 10 and a gap extension penalty of 0.5), and (3) no penalty for terminal gaps.

[0032] As an example of the present application, the mutant SpoT protein of the present application may have an activity of SpoT protein, or may have an activity that improves L-amino acid producing ability compared to a wild-type polypeptide having the activity of SpoT protein.

[0033] In the present application, the term "SpoT protein" refers to a polypeptide having activity of degrading and / or synthesizing (p)ppGpp. Specifically, the SpoT protein in the present application is used interchangeably with bifunctional (p)ppGpp synthase and bifunctional (p)ppGpp hydrolase. In the present application, the sequence of the SpoT protein can be obtained from GenBank of NCBI, which is a publicly known database. Specifically, the SpoT protein is a polypeptide encoded by the spoT gene, but is not limited thereto.

[0034] In one embodiment, the SpoT protein of the present application may be derived from Escherichia sp. In one embodiment, the SpoT protein of the present application may be the amino acid sequence of SEQ ID NO: 1. In one embodiment, the SpoT protein of the present application may include an amino acid sequence having 70% or more, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or more homology or identity to the amino acid sequence of SEQ ID NO: 1, but is not limited thereto.

[0035] "Corresponding to" in this application means the amino acid residue at the recited position in the polypeptide, or an amino acid residue similar, identical or equivalent to the recited residue in the polypeptide. Identifying the amino acid at the corresponding position will determine the particular amino acid of the sequence to which the particular sequence is referenced. "Corresponding region" in this application generally refers to a similar or corresponding position in a related or reference protein.

[0036] For example, any amino acid sequence can be aligned with SEQ ID NO: 1, and based thereon, each amino acid residue of the amino acid sequence can be numbered with reference to the number and position of the amino acid residues corresponding to the amino acid residues in SEQ ID NO: 1. For example, the sequence alignment algorithm in the present application can identify the positions of amino acids or positions where modifications such as substitutions, insertions, deletions, etc. occur when compared to a query sequence (also referred to as a "reference sequence").

[0037] For such alignment, for example, the Needleman-Wunsch algorithm (Non-Patent Document 6) or the Needle program in the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Non-Patent Document 5) can be used, but is not limited to these. Sequence alignment programs and pairwise sequence comparison algorithms known in the technical field can be used as appropriate.

[0038] Another aspect of the present application provides a polynucleotide encoding a mutant SpoT protein of the present application.

[0039] In the present application, the term "polynucleotide" refers to a nucleotide polymer in which nucleotide monomers are covalently linked in a long chain, and means a DNA or RNA chain longer than a certain length, and more specifically, refers to a polynucleotide fragment encoding the mutant SpoT protein.

[0040] A polynucleotide encoding a mutant SpoT protein of the present application may comprise a nucleotide sequence encoding an amino acid sequence comprising a substitution of the amino acid at position 262 in SEQ ID NO: 1 with another amino acid. In one embodiment, a polynucleotide of the present application may comprise a nucleotide sequence encoding an amino acid sequence of any of SEQ ID NOs: 19 to 24, may consist of said nucleotide sequence, or may essentially consist of said nucleotide sequence.

[0041] The polynucleotide of the present application may be modified in various ways in the coding region, taking into consideration the codon degeneracy or the codons preferred in the organism in which the mutant protein of the present application is to be expressed, as long as the amino acid sequence of the mutant protein of the present application is not changed. Specifically, the polynucleotide of the present application has a base sequence having 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, and less than 100% homology or identity to the sequence of SEQ ID NO: 2, or includes the base sequence, or consists of a base sequence having 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, and less than 100% homology or identity to the sequence of SEQ ID NO: 2, or is substantially composed of the base sequence, but is not limited thereto. Here, in the sequence having the homology or identity, the codon encoding the amino acid corresponding to the 262nd position of SEQ ID NO: 1 may be one of the codons encoding an amino acid other than alanine, specifically an amino acid selected from glycine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine and histidine.

[0042] Furthermore, the polynucleotide of the present application may be any sequence that hybridizes under stringent conditions with a probe prepared from a known gene sequence, for example, a complementary sequence to all or a part of the polynucleotide sequence of the present application. The term "stringent conditions" refers to conditions that allow specific hybridization between polynucleotides. Such conditions are specifically described in the literature (see Non-Patent Document 14). For example, the conditions include conditions under which polynucleotides having high homology or identity, such as polynucleotides having a homology or identity of 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, hybridize with each other, but polynucleotides having lower homology or identity than that do not hybridize with each other, or conditions under which washing is performed once, specifically two to three times, at a salt concentration and temperature equivalent to normal Southern hybridization washing conditions of 60°C, 1 x SSC, 0.1% SDS, specifically 60°C, 0.1 x SSC, 0.1% SDS, more specifically 68°C, 0.1 x SSC, 0.1% SDS.

[0043] Hybridization requires that two nucleic acids have complementary sequences, even though mismatches between bases are possible depending on the stringency of hybridization. "Complementary" is used to describe the relationship between nucleotide bases that can hybridize with each other. For example, in DNA, adenosine is complementary to thymine, and cytosine is complementary to guanine. Thus, the polynucleotides of the present application may include isolated nucleic acid fragments that are complementary to the entire sequence, as well as substantially similar nucleic acid sequences.

[0044] Specifically, polynucleotides having homology or identity to the polynucleotides of the present application can be detected using the hybridization conditions described above, in which the hybridization step is performed at a Tm value of 55° C. The Tm value may be, but is not limited to, 60° C., 63° C., or 65° C., and may be appropriately adjusted by those skilled in the art depending on the purpose.

[0045] The appropriate stringency for hybridizing the polynucleotides depends on the length of the polynucleotides and the degree of complementation, variables known in the art (eg, Non-Patent Document 14).

[0046] Yet another aspect of the present application provides a vector comprising a polynucleotide of the present application, the vector being, but not limited to, an expression vector for expressing the polynucleotide in a host cell.

[0047] In the present application, the term "vector" refers to a DNA product comprising a base sequence of a polynucleotide encoding a target polypeptide operably linked to a suitable expression control region (or expression control sequence) so that the target polypeptide can be expressed in a suitable host. The expression control region includes a promoter for initiating transcription, an optional operator sequence for regulating the transcription, a sequence encoding a suitable mRNA ribosome binding site, and a sequence for regulating the termination of transcription and translation. When transformed into a suitable host cell, the vector can replicate and function independently of the host genome, and is integrated into the genome itself.

[0048] The vector used in the present application is not particularly limited, and any vector known in the art may be used. Examples of commonly used vectors include plasmids, cosmids, viruses, and bacteriophages in a natural or recombinant state. For example, pWE15, M13, MBL3, MBL4, IXII, ASHII, APII, t10, t11, Charon4A, Charon21A, etc. may be used as phage or cosmid vectors, and pDZ, pBR, pUC, pBluescriptII, pGEM, pTZ, pCL, pET, etc. may be used as plasmid vectors. Specifically, pDZ, pDC, pDCM2, pACYC177, pACYC184, pCL, pECCG117, pUC19, pBR322, pMW118, pCC1BAC vectors, etc. may be used.

[0049] For example, a polynucleotide encoding a target polypeptide can be inserted into a chromosome by a vector for intracellular chromosome introduction. The polynucleotide can be inserted into a chromosome by any method known in the art, such as, but not limited to, homologous recombination. A selection marker for confirming whether or not the target nucleic acid molecule has been introduced into the chromosome may be further included. The selection marker is for selecting cells transformed with the vector, i.e., for confirming whether or not the target nucleic acid molecule has been inserted, and a marker that confers a selectable phenotype such as drug resistance, auxotrophy, resistance to cytotoxic agents, or expression of a surface polypeptide is used. In an environment treated with a selection agent, only cells expressing the selection marker survive or show a different phenotype, so that transformed cells can be selected.

[0050] In the present application, "transformation" means introducing a vector containing a polynucleotide encoding a target polypeptide into a host cell or a microorganism, thereby expressing the polypeptide encoded by the polynucleotide in the host cell. The transformed polynucleotide may be any polynucleotide that is expressed in the host cell, regardless of whether it is inserted into the chromosome of the host cell or located extrachromosomally. The polynucleotide may include DNA and / or RNA that encodes the target polypeptide. The polynucleotide may be introduced in any form as long as it is introduced into the host cell and expressed. For example, the polynucleotide may be introduced into the host cell in the form of an expression cassette, which is a genetic structure containing all elements necessary for its own expression. Typically, the expression cassette contains a promoter, a transcription termination signal, a ribosome binding site, and a translation termination signal operably linked to the polynucleotide. The expression cassette may be in the form of a self-replicating expression vector. The polynucleotide may be introduced into the host cell in its own form and operably linked to a sequence necessary for expression in the host cell, but is not limited thereto.

[0051] Additionally, the term "operably linked" means that the polynucleotide sequence is functionally linked to a promoter sequence that initiates and mediates transcription of the polynucleotide encoding the target variant of the present application.

[0052] Yet another aspect of the present application provides a microorganism of the genus Escherichia comprising at least one of a mutant SpoT protein of the present application, a polynucleotide encoding the mutant SpoT protein, and a vector comprising the polynucleotide.

[0053] The microorganism of the present application may comprise a mutant SpoT protein of the present application, a polynucleotide encoding the mutant protein, or a vector comprising a polynucleotide of the present application.

[0054] In one embodiment, the microorganism of the present application expresses the mutant SpoT protein of the present application by containing a mutant SpoT protein of the present application, a polynucleotide encoding the mutant protein, or a vector containing a polynucleotide of the present application.

[0055] In the present application, the term "strain (or microorganism)" includes all wild-type microorganisms and microorganisms that have been genetically modified, either naturally or artificially, and may be a microorganism in which a specific mechanism has been weakened or enhanced by, for example, inserting an exogenous gene or enhancing or inactivating the activity of an endogenous gene, and may also be a microorganism that has been genetically modified for the production of a desired polypeptide, protein, or product.

[0056] Strains of the present application include, but are not limited to, strains comprising at least one of the mutant proteins of the present application, the polynucleotides of the present application, and vectors comprising the polynucleotides of the present application, strains modified to express the mutant proteins of the present application or the polynucleotides of the present application, strains (e.g., recombinant strains) that express the mutant proteins of the present application or the polynucleotides of the present application, or strains (e.g., recombinant strains) that have activity of the mutant proteins of the present application.

[0057] The strain of the present application may be a strain capable of producing an L-amino acid.

[0058] In one embodiment, the L-amino acid may be L-tryptophan.

[0059] The strain of the present application is a microorganism that naturally has the SpoT protein or L-amino acid production ability, or a parent strain that does not have the SpoT protein or L-amino acid production ability into which a mutant SpoT protein of the present application or a polynucleotide encoding it (or a vector containing the polynucleotide) has been introduced and / or which has been conferred the ability to produce L-amino acids, but is not limited to these.

[0060] For example, the strain of the present application is a cell or microorganism transformed with a vector containing the polynucleotide of the present application or a polynucleotide encoding the mutant protein of the present application and expressing the mutant protein of the present application, and the strain of the present application may be any microorganism that contains the mutant protein of the present application and produces an L-amino acid. For example, the strain of the present application may be a recombinant strain in which an SpoT mutant is expressed and L-amino acid production ability is improved by introducing a polynucleotide encoding the mutant of the present application into a natural wild-type microorganism or a microorganism that produces an L-amino acid. The recombinant strain with improved L-amino acid production ability is a microorganism with improved L-amino acid production ability compared to a natural wild-type microorganism or a microorganism with unmodified SpoT (i.e., a microorganism expressing a wild-type SpoT protein), but is not limited thereto. For example, the SpoT protein unmodified microorganism, which is the subject strain to be compared for whether the L-amino acid production ability is improved, is CA04-4303 or KCCM11166P strain, but is not limited thereto.

[0061] For example, the recombinant strain with improved L-amino acid production ability has an improved L-amino acid production ability of at least about 5%, at least 6%, or at least 8% compared to the parent strain or unmodified microorganism before mutation, but may be any value that shows an increase in + value compared to the production ability of the parent strain or unmodified microorganism before mutation. The term "about" refers to a range that includes ±0.5, ±0.4, ±0.3, ±0.2, ±0.1, etc., and may be any value that is equal to or in a similar range to the value following the term "about," but is not limited thereto.

[0062] In the present application, the term "unmodified microorganism" does not exclude strains containing mutations that may occur naturally in microorganisms, but refers to a wild-type strain or a natural strain itself, or a strain before its characteristics are changed due to genetic mutation caused by natural or artificial factors. For example, the unmodified microorganism refers to a strain into which the mutant SpoT protein of the present application has not been introduced or before it has been introduced. The term "unmodified microorganism" is used interchangeably with "strain before modification," "microorganism before modification," "non-mutated strain," "non-modified strain," "non-mutated microorganism," or "reference microorganism."

[0063] In another embodiment of the present application, the microorganism of the present application may be a microorganism of the genus Escherichia, specifically, but not limited to, Escherichia coli.

[0064] The mutant SpoT protein, polynucleotide, L-amino acids, and the like in the microorganism of the present application are as described above.

[0065] Yet another aspect of the present application provides a method for producing an L-amino acid, comprising the step of culturing the Escherichia microorganism of the present application in a medium.

[0066] The method for producing an L-amino acid of the present application may include a step of culturing an Escherichia strain containing a mutant SpoT protein of the present application, a polynucleotide of the present application, or a vector of the present application in a medium.

[0067] In one embodiment, the L-amino acid may be L-tryptophan.

[0068] In the present application, "culturing" refers to growing the Escherichia strain of the present application under appropriately adjusted environmental conditions. The culturing process of the present application can be carried out in a suitable medium and under suitable culture conditions known in the art. Such a culturing process can be easily adjusted and used by a person skilled in the art depending on the strain selected. Specifically, the culturing can be batch, continuous and / or fed-batch culture, but is not limited thereto.

[0069] The term "culture medium" in the present application refers to a mixture of nutrients necessary for culturing the strains of the genus Escherichia of the present application as the main components, and supplies nutrients such as water essential for survival and growth, growth factors, etc. Specifically, the medium and other culture conditions used for culturing the strains of the genus Escherichia of the present application may be any medium used for culturing ordinary microorganisms, and the strains of the genus Escherichia of the present application can be cultured in an ordinary medium containing suitable carbon sources, nitrogen sources, phosphorus sources, inorganic compounds, amino acids and / or vitamins, etc., under aerobic conditions by controlling the temperature, pH, etc.

[0070] The carbon source in the present application may be carbohydrates such as glucose, saccharose, lactose, fructose, sucrose, maltose, etc., sugar alcohols such as mannitol, sorbitol, etc., organic acids such as pyruvic acid, lactic acid, citric acid, etc., amino acids such as glutamic acid, methionine, lysine, etc. Also, natural organic nutrient sources such as starch hydrolysates, molasses, blackstrap molasses, rice bran, cassava, bagasse, corn steeping liquid, etc. may be used, specifically, carbohydrates such as glucose and sterilized pretreated molasses (i.e., molasses converted into reducing sugars) may be used, and any other suitable carbon source may be used. These carbon sources may be used alone or in combination of two or more, but are not limited thereto.

[0071] The nitrogen source may be an inorganic nitrogen source such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, ammonium carbonate, or ammonium nitrate, or an organic nitrogen source such as an amino acid such as glutamic acid, methionine, or glutamine, peptone, NZ-amine, meat extract, yeast extract, malt extract, corn steeping liquid, casein hydrolysate, fish or its decomposition product, or defatted soybean cake or its decomposition product. These nitrogen sources may be used alone or in combination of two or more kinds, but are not limited thereto.

[0072] The phosphorus source may be potassium dihydrogen phosphate, dipotassium hydrogen phosphate, or a sodium-containing salt equivalent thereto. The inorganic compound may be sodium chloride, calcium chloride, iron chloride, magnesium sulfate, iron sulfate, manganese sulfate, calcium carbonate, or other suitable compounds, such as amino acids, vitamins, and / or suitable precursors. These components or precursors may be added to the medium in a batch or continuous manner. However, they are not limited thereto.

[0073] In addition, during the cultivation of the Escherichia strain of the present application, compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, and sulfuric acid may be added to the medium in a suitable manner to adjust the pH of the medium. Furthermore, during the cultivation, foam generation may be suppressed using an antifoaming agent such as fatty acid polyglycol ester. Furthermore, in order to maintain the aerobic state of the medium, oxygen or an oxygen-containing gas may be injected into the medium, and in order to maintain the anaerobic and microaerobic states, no gas may be injected, and nitrogen, hydrogen, or carbon dioxide gas may be injected, but is not limited to these.

[0074] In the culture of the present application, the culture temperature is maintained at 20 to 45° C., specifically 25 to 40° C., and the culture is carried out for about 10 to 160 hours, but is not limited thereto.

[0075] The L-amino acids produced by the culture of the present application are either secreted into the medium or remain intracellularly.

[0076] The L-amino acid production method of the present application may further include a step of preparing an Escherichia strain of the present application, a step of preparing a medium for culturing the strain, or a combination thereof (in any order), for example prior to the culturing step.

[0077] The method for producing an L-amino acid of the present application may further include a step of recovering the L-amino acid from the medium used for the culture (the medium in which the culture was carried out) or from the Escherichia strain of the present application. The recovery step may be further included after the culture step.

[0078] The recovery may involve collecting the target L-amino acid using a suitable method known in the art depending on the culture method of the microorganism of the present application, such as batch, continuous, or fed-batch culture. For example, centrifugation, filtration, crystallization, treatment with a protein precipitant (salting out), extraction, ultrasonic disruption, ultrafiltration, dialysis, various chromatographies such as molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, and affinity chromatography, HPLC, or a combination thereof may be used to recover the target L-amino acid from the medium or the microorganism using a suitable method known in the art.

[0079] The L-amino acid production method of the present application may further include a purification step. The purification may be performed by any suitable method known in the art. For example, when the L-amino acid production method of the present application includes both a recovery step and a purification step, the recovery step and the purification step may be performed at different times (or consecutively) regardless of the order, or may be performed simultaneously or integrated into one step, but is not limited thereto.

[0080] The mutant SpoT protein, polynucleotide, vector, strain, etc. in the method of the present application are as described above.

[0081] Yet another aspect of the present application provides a composition for producing L-amino acids, comprising the mutant SpoT protein of the present application.

[0082] In one embodiment, the composition may comprise a mutant SpoT protein of the present application, a polynucleotide encoding the mutant SpoT protein, a vector comprising the polynucleotide, or an Escherichia strain comprising the polynucleotide of the present application, or may comprise a culture thereof, or may comprise a combination of two or more thereof.

[0083] The composition of the present application may further contain any suitable excipient that is commonly used in compositions for producing amino acids, including, but not limited to, preservatives, wetting agents, dispersing agents, suspending agents, buffers, stabilizers, isotonicity agents, etc.

[0084] The mutant SpoT protein, polynucleotide, vector, strain, medium, L-amino acid, and the like in the composition of the present application are as described above.

[0085] Yet another aspect of the present application provides a method for improving an L-amino acid producing ability of a microorganism, comprising the step of modifying the microorganism to express a mutant SpoT protein of the present application.

[0086] Yet another aspect of the present application provides use of the mutant SpoT protein of the present application in producing L-amino acids.

[0087] The mutant SpoT protein, the microorganism, the L-amino acids, etc. are as described above.

[0088] In this specification, unless otherwise specified, the terms "comprise," "have," "contain," and the like are intended to mean the inclusion of a specified integer or set of integers, but are not intended to exclude other integers or sets of integers. EXAMPLES

[0089] The present application will be described in detail below with reference to examples. However, these examples are merely illustrative of the present application, and the present application is not limited to these examples.

[0090] Example 1 Construction of recombinant vector pSKH-spoT In order to obtain a DNA fragment of about 1.63 kb containing the mutation site of the gene spoT (SEQ ID NO: 2), chromosomal DNA (gDNA) of the wild-type E. coli strain W3110 was extracted using the Genomic-tip system of Qiagen, and PCR (polymerase chain reaction) was performed using the gDNA as a template and a PCR HL premix kit (BIONEER, the same applies below). In order to amplify the gene fragment site in which the 262nd amino acid alanine in the SpoT amino acid sequence (SEQ ID NO: 1) was replaced with other polar amino acids serine (S), threonine (T), cysteine ​​(C), tyrosine (Y), asparagine (N), and glutamine (Q), PCR was performed using the primer set in Table 1, repeating 27 cycles consisting of denaturation at 95°C for 30 seconds, annealing at 56°C for 30 seconds, and elongation at 68°C for 1 minute.

[0091] As a result, gene fragments measuring 0.82 kb and 0.88 kb were obtained by substitution mutation.

[0092] [Table 1]

[0093] The amplified mutant spoT gene fragment and the chromosomal transformation vector pSKH vector (Patent Document 1) digested with EcoR V restriction enzyme were cloned by the Gibson assembly method (Non-Patent Document 15) to obtain recombinant plasmids, which were named pSKH-spoT(A262S), pSKH-spoT(A262T), pSKH-spoT(A262C), pSKH-spoT(A262Y), pSKH-spoT(A262N), and pSKH-spoT(A262Q) according to the substituted mutations. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment in calculated molar amounts, and then storing at 50°C for 1 hour.

[0094] Example 2 Development of a mutant strain in which the 262nd amino acid coding sequence of SpoT is replaced with a polar amino acid coding sequence. The pSKH-spoT(A262S), pSKH-spoT(A262T), pSKH-spoT(A262C), pSKH-spoT(A262Y), pSKH-spoT(A262N), and pSKH-spoT(A262Q) obtained in Example 1 were transformed into electro-competent cells of the L-tryptophan producing strain KCCM11166P (Patent Document 2) by electroporation, and then a secondary crossover process was performed to obtain a strain in which the coding sequence of alanine, the 262nd amino acid of SpoT on the chromosome, was replaced with the coding sequence of polar amino acids serine, threonine, cysteine, tyrosine, asparagine, and glutamine (SEQ ID NOs: 19 to 24). The genetic manipulation was confirmed by PCR using primers of SEQ ID NOs: 3 and 4, which respectively amplify the external sites of the upstream and downstream regions of homologous recombination into which the gene was inserted, and genome sequencing. Sequence number 3 (spoT-confirm forward) CCAGGAACAGCAAGAGCA Sequence number 4 (spoT-confirm reverse) ACGGATATTACGGCAGGA

[0095] The strains obtained in this manner were named E. coli KCCM11166P::spoT(A262S), KCCM11166P::spoT(A262T), KCCM11166P::spoT(A262C), KCCM11166P::spoT(A262Y), KCCM11166P::spoT(A262N), and KCCM11166P::spoT(A262Q).

[0096] In addition, whether the introduction of the above-mentioned mutation at the 262nd position of SpoT has the same effect in other L-tryptophan producing strains of the genus Escherichia was confirmed in another L-tryptophan producing strain, CA04-4303 (Patent Document 3). CA04-4303 is a strain in which trpR, mtr, and tnaA are deleted in the wild-type W3110 strain, and the 21st amino acid of trpE is replaced from proline to serine. A strain was prepared in which the coding sequence of alanine, the 262nd amino acid of SpoT on the chromosome of the CA04-4303 strain, was replaced with the coding sequence of polar amino acids serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The preparation process was the same as the introduction process of KCCM11166P described above.

[0097] The strains obtained in this manner were designated CA04-4303::spoT(A262S), CA04-4303::spoT(A262T), CA04-4303::spoT(A262C), CA04-4303::spoT(A262Y), CA04-4303::spoT(A262N), and CA04-4303::spoT(A262Q).

[0098] Example 3 Comparison of L-tryptophan productivity in mutant strains in which the 262nd amino acid of SpoT was replaced with a polar amino acid The L-tryptophan producing strain KCCM11166P-based strain prepared in Example 2 in which the 262nd amino acid of SpoT was replaced with a polar amino acid was cultured in a tryptophan titer medium prepared with the composition shown in Table 2, and its L-tryptophan producing ability was confirmed.

[0099] [Table 2]

[0100] Specifically, E. coli KCCM11166P and E. coli KCCM11166P::spoT(A262S), KCCM11166P::spoT(A262T), KCCM11166P::spoT(A262C), KCCM11166P::spoT(A262Y), KCCM11166P::spoT(A262N), and KCCM11166P::spoT(A262Q) that had been cultured overnight in LB solid medium in an incubator at 37°C were inoculated into 25 mL of the titer medium in Table 2, one loopful at a time, and then cultured in an incubator at 37°C and 200 rpm for 48 hours, and the sugar consumption rate and L-tryptophan concentration were compared.

[0101] As a result, as shown in Table 3, the sugar consumption observed after 22 hours of culture in the control KCCM11166P strain was 25.0 g / L, while the sugar consumption in the same time period in the mutant strain in which the 262nd amino acid in the SpoT protein amino acid sequence was replaced with a polar amino acid was 27-31 g / L. This represents an 8.8%-25.8% increase in productivity, and it was confirmed that the productivity of KCCM11166P::spoT(A262T) in particular was most significantly improved.

[0102] These results confirmed that the 262nd amino acid position of SpoT protein is the key region for changing the activity of the protein, which means that the substitution of the 262nd amino acid with a polar amino acid significantly improves the productivity of L-tryptophan fermentation.

[0103] [Table 3]

[0104] The change in L-tryptophan productivity due to the substitution of the 262nd amino acid of SpoT with a polar amino acid was also confirmed in the CA04-4303 strain obtained in Example 2. The culture method and medium composition for comparing L-tryptophan productivity were the same as those for the KCCM11166P-based culture.

[0105] As can be seen from the following results, it was confirmed that the mutation selected in the present application significantly improved L-tryptophan productivity, even in the case of the amino acid substitution at position 262 of SpoT based on the L-tryptophan-producing strain CA04-4303.

[0106] As shown in Table 4, the sugar consumption observed after 22 hours of culture in the control CA04-4303 strain was 30.0 g / L, while the sugar consumption in the same time period in the mutant strain in which the 262nd amino acid in the amino acid sequence of the SpoT protein was replaced with a polar amino acid was 31.8 to 33.0 g / L. This represents a 13.0% to 30.4% increase in productivity, and it was confirmed that the productivity of CA04-4303::spoT(A262Y) in particular was most significantly improved.

[0107] [Table 4]

[0108] These results suggest that L-amino acid productivity is improved in an Escherichia microorganism into which a mutant SpoT in which the 262nd amino acid in the amino acid sequence of the present application is replaced with a polar amino acid, and as a result, L-amino acid productivity is improved compared to that of an unmodified strain.

[0109] From the above description, a person skilled in the art to which the present invention pertains will understand that the present invention can be implemented in other specific forms without changing its technical ideas or essential features. It should be understood that the above examples are merely illustrative and not limiting. The present invention should be interpreted as including all modifications and alterations derived from the meaning and scope of the claims and their equivalent concepts, rather than the specification.

Claims

1. A mutant SpoT protein comprising a substitution of an amino acid corresponding to position 262 in the sequence of SEQ ID NO: 1 with another amino acid, the other amino acids being selected from serine, threonine, cysteine, tyrosine, asparagine and glutamine; A mutant SpoT protein having a sequence identity of 90% or more but less than 100% with the amino acid sequence of SEQ ID NO:

1.

2. A mutant SpoT protein described in claim 1, comprising any one of the amino acid sequences represented by SEQ ID NOs: 19 to 24.

3. A polynucleotide encoding the mutant SpoT protein according to claim 1 or 2.

4. 3. A microorganism belonging to the genus Escherichia (Escherichia sp.), comprising at least one of the mutant SpoT protein according to claim 1 or 2 and a polynucleotide encoding said mutant SpoT protein.

5. The Escherichia microorganism according to claim 4, wherein the Escherichia microorganism is Escherichia coli.

6. The microorganism of the genus Escherichia according to claim 4, which produces an L-amino acid.

7. The Escherichia microorganism according to claim 6, wherein the L-amino acid is L-tryptophan.

8. A method for producing an L-amino acid, comprising the step of culturing the Escherichia microorganism according to claim 4 in a medium.

9. The method for producing an L-amino acid according to claim 8, wherein the L-amino acid is L-tryptophan.

10. The method for producing an L-amino acid according to claim 8, further comprising the step of recovering the L-amino acid from the microorganism or the medium.

11. 3. A composition for producing an L-amino acid, comprising the mutant SpoT protein according to claim 1 or 2, a microorganism belonging to the genus Escherichia expressing the mutant SpoT protein, or a culture of the microorganism.

12. A method for improving an L-amino acid producing ability of a microorganism, comprising the step of modifying the microorganism so that the microorganism expresses the mutant SpoT protein according to claim 1 or 2.

Images